Hangzhou Xuzhishi Technology

Hangzhou Xuzhishi Technology, legally known as Hangzhou Xuzhishi Technology Co., Ltd., is a company operating at the intersection of artificial intelligence, brain science, and digital therapeutics. Founded in 2015 by Kang Cheng, who holds a significant stake in the business, the company is headquartered in Hangzhou, China. It has established itself by developing digital medical solutions for brain diseases, securing its position as a specialized and high-tech enterprise.

The company's core business revolves around creating digital therapies that utilize technologies like virtual reality (VR), AI, and brain imaging to address a range of neurological and psychiatric conditions. Its product suite is designed to assist in the treatment of cognitive impairments across departments such as neurology, psychiatry, pediatrics, and rehabilitation. A key offering is a VR-based treatment product for cognitive dysfunction, which has notably received a medical device registration certificate in China and has been implemented in over 200 hospitals. This system works by creating immersive virtual environments that stimulate a patient's brain to improve cognitive functions. The technology also integrates real-time monitoring of physiological signals like EEG, eye-tracking, ECG, and skin conductivity to dynamically adjust and personalize rehabilitation plans.

Xuzhishi Technology's business model appears to be centered on the development and sale of these regulated medical device solutions to healthcare institutions. Having secured several rounds of funding, including a significant Series A in late 2024 led by Star Capital, the company is focused on expanding its product development for both domestic and international markets. The firm has successfully obtained certifications such as the EU's CE mark, allowing it to export its products overseas. The company's journey began with its founding investment in 2016, leading to the successful development of its cognitive rehabilitation VR solution by 2018 and achieving regulatory approval for its software as a Class II medical device in 2020, marking its commercial entry.

Keywords: digital therapeutics, brain science, virtual reality therapy, cognitive rehabilitation, medical AI, neurological disorders, psychiatric technology, brain imaging, digital health, neuro-rehabilitation, EEG monitoring, personalized therapy, medical device, CE mark, mental health technology, brain-computer interface, Hangzhou, AI healthcare, neurotechnology, cognitive function